Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

CTLA-4 immune checkpoint inhibition

Name: Health-related QoL in ipilimumab treated advanced melanoma survivors
Uploaded: 2019-09-27T00:00:00Z
Duration: 1 min 27 s
Description: Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the health-related quality of life of advanced melanoma survivors treated with ipilimumab (CTLA-4 immune checkpoint inhibition) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Sorry, no posts matched your criteria.

CTLA-4 immune checkpoint inhibition

Cookie settings